AM
Therapeutic Areas
GliaPharm Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lead Program (undisclosed) | Alzheimer's Disease | Preclinical |
| Epilepsy Program | GLUT1 Deficiency Syndrome (Epilepsy) | Preclinical |
| ALS Research | Amyotrophic Lateral Sclerosis | Research |
Leadership Team at GliaPharm
LB
Leon Bushara
Executive Chairman
PP
Prof. Pierre J. Magistretti, MD, PhD
Scientific Founder, Chairman of the Scientific Advisory Board
DS
Dr. Sylvain Lengacher, PhD
Leadership Team
DC
Dr. Charles Finsterwald, PhD
Leadership Team
DF
Dr. Francois Jenck, PhD
Leadership Team
DU
Dr. Uwe Meya, MD
Leadership Team